ACTRIMS 2023 | Future studies on damaging pathways associated with MS progression & severity

Previous studies have identified potential pathways associated with multiple sclerosis (MS) progression or severity. Peter Kosa, PhD, National Institutes of Health, Bethesda, MD, explains that the next step would be to look at those individual pathways and generate cell culture models to study the mechanistic details at a molecular level. Notably, the identification of damaging pathways can enable the identification of inhibitors that could be used as potential MS treatments. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.